Name: ECS Botanics Holdings (ECS) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

ECS

Pharmaceuticals, Biotechnology & Life Sciences

ECS Botanics Holdings

Short interest: 0.13%; +0.12 pp 30d; as of 27 Feb 2024
Reported shorts: 1.5M
Shares on issue: 1.107B

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About ECS Botanics Holdings

ECS Botanics Holdings (ASX:ECS) is an Australian industrial hemp and medicinal cannabis company operating within the Pharmaceuticals, Biotechnology & Life Sciences sector. The company focuses on the organic cultivation and production of high-quality medicinal cannabis products, adhering to PIC/S GMP standards for comprehensive quality control from harvest to storage. Their business model emphasizes providing affordable, naturally grown products to end-users.

Company profile →

ECS Botanics Holdings (ASX:ECS) has 0.13% of its shares on issue reported as short positions as of 27 Feb 2024, or about 1,463,285 shares. Over the past 30 days that figure has risen 0.12 percentage points, and over 90 days it has risen 0.12 percentage points. ECS is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads ECS today

Zanger BreakoutWatchScore 6rank 1847 of 1893
CAN SLIMNot a candidate
Minervini Trend TemplateWatchScore 7rank 1494 of 1684
Crowded-Short BreakoutWatchScore 9rank 1034 of 1448
Quality compoundersWatchScore 8rank 1423 of 1660

Prices to 15 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

ECS fundamentals

In the year to 30 Jun 2026, ECS Botanics Holdings (ASX:ECS) recorded revenue of A$21.4M and a net loss after tax of A$1.9M. A year earlier it recorded revenue of A$19.5M and a net loss after tax of A$5.7M. Year-on-year growth: revenue +9.9% (FY). Net margin −8.9% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit), as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →